Armen Mardiros

Armen Mardiros has over 18 years of work experience in the field of biomedical research and development. Armen is currently serving as the Director of Translational Science at A2 Biotherapeutics, Inc. Prior to that, they held the same position at Allogene Therapeutics from July 2020 to January 2021. Armen also served as the Associate Director of Translational Science at Allogene Therapeutics from April 2019 to July 2020.

Armen gained significant experience at Kite Pharma, Inc., where they worked for almost five years. Armen started as an Associate Scientist in May 2014 and was promoted to Senior Scientist in July 2016. Later, they became a Principal Scientist and served in that role from August 2018 to March 2019.

Before joining Kite Pharma, Armen pursued their Ph.D. at City of Hope, where they worked as a Ph.D. candidate from 2009 to May 2014. During this time, they developed a chimeric antigen receptor redirected T cell to target acute myeloid leukemia under the mentorship of Dr. Stephen J.

Armen began their research career as a Research Associate II at Cedars-Sinai Medical Center in 2008, where they focused on improving dendritic cell vaccination therapy for glioblastoma multiforme in Dr. Christopher Wheeler's laboratory.

Armen started their academic journey as a Laboratory Assistant at UCLA from 2003 to 2005. Later, Armen joined California State University, Northridge, where they worked as a Graduate Research Assistant, Graduate Assistant, and Laboratory Instructor from 2005 to 2009. Their thesis defense at CSUN was on Nucleotide Excision Repair (NER) in Saccharomyces cerevisiae under the guidance of Dr. Paula L.

Overall, Armen Mardiros has a diverse and extensive background in translational science, cancer immunotherapy, and cellular therapy development, making him a valuable asset to any organization in the field.

Armen Mardiros completed their Bachelor of Science (B.S.) in Biochemistry from UCLA in 2005. Armen then went on to pursue a Master's degree in Biochemistry at California State University, Northridge from 2005 to 2009. Following this, they attended the Irell and Manella Graduate School of Biological Sciences at City of Hope National Medical Center from 2009 to 2014, where they obtained their Ph.D. in Biological Sciences with a focus on T cell Immunotherapy.